Bristol-Myers Squibb (BMY) Stock Forecast & Price Target

$48.44

-0.54 (-1.10%)

(As of 08/21/2024 ET)

Bristol-Myers Squibb - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 16 Analyst Ratings

Based on 16 Wall Street analysts who have issued ratings for Bristol-Myers Squibb in the last 12 months, the stock has a consensus rating of "Hold." Out of the 16 analysts, 1 has given a sell rating, 13 have given a hold rating, and 2 have given a buy rating for BMY.

Consensus Price Target

$54.86
13.25% Upside

High Forecast	$84.00
Average Forecast	$54.86
Low Forecast	$41.00

According to the 16 analysts' twelve-month price targets for Bristol-Myers Squibb, the average price target is $54.86. The highest price target for BMY is $84.00, while the lowest price target for BMY is $41.00. The average price target represents a forecasted upside of 13.25% from the current price of $48.44.

Type	Current Forecast 8/23/23 to 8/22/24	1 Month Ago 7/24/23 to 7/23/24	3 Months Ago 5/25/23 to 5/24/24	1 Year Ago 8/23/22 to 8/23/23
Consensus Rating	Hold	Hold	Hold	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)	6 Buy rating(s)
Hold	13 Hold rating(s)	13 Hold rating(s)	15 Hold rating(s)	8 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$54.86	$57.73	$60.00	$71.14
Forecasted Upside	13.25% Upside	13.64% Upside	12.81% Upside	10.97% Upside

Get Bristol-Myers Squibb Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.

Ad Behind the Markets

270x more lucrative than NVIDIA???

If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that could be a lot more lucrative.

Get the ticker here >>>

BMY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BMY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Bristol-Myers Squibb Stock vs. The Competition

Type	Bristol-Myers Squibb	Medical Companies	S&P 500
Consensus Rating Score	2.06	2.75	2.51
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	13.25% Upside	5,585.32% Upside	8.74% Upside
News Sentiment Rating	Positive News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/12/2024	TD Cowen 4 of 5 stars		Boost Target	Hold ➝ Hold	$45.00 ➝ $53.00	+12.15%
7/29/2024	Barclays 3 of 5 stars		Downgrade	Overweight ➝ Equal Weight	$41.00 ➝ $41.00	-18.73%
7/23/2024	Deutsche Bank Aktiengesellschaft 2 of 5 stars		Lower Target	Hold ➝ Hold	$53.00 ➝ $45.00	+5.36%
7/22/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$45.00 ➝ $45.00	+5.14%
4/26/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Market Perform ➝ Market Perform	$55.00 ➝ $48.00	+6.29%
4/18/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$51.00 ➝ $52.00	+8.11%
Get the Latest News and Ratings for BMY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Bristol-Myers Squibb and its competitors with MarketBeat's FREE daily newsletter.
4/1/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Phipps Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
3/11/2024	Societe Generale Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
2/6/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$77.00 ➝ $54.00	+12.50%
1/3/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$68.00 ➝ $60.00	+13.67%
11/2/2023	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$68.00 ➝ $54.00	+5.30%
10/30/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$81.00 ➝ $69.00	+35.48%
10/27/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Underweight ➝ Underweight	$56.00 ➝ $50.00	-5.63%
10/27/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Reduce ➝ Hold	$55.00 ➝ $53.00	+0.03%
10/20/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$70.00 ➝ $60.00	+6.29%
10/6/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$84.00	+47.91%
7/28/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight	$90.00 ➝ $85.00	+39.89%
7/12/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$72.00 ➝ $66.00	+5.13%
7/10/2023	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
7/10/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$66.00	+5.35%
4/28/2023	51job Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
3/6/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$62.00	-10.53%
10/10/2022	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral
9/14/2022	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$82.00 ➝ $76.00	+6.98%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:01 AM ET.

BMY Forecast - Frequently Asked Questions

What is Bristol-Myers Squibb's forecast for 2024?: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Bristol-Myers Squibb is $54.86, with a high forecast of $84.00 and a low forecast of $41.00.
Should I buy or sell Bristol-Myers Squibb stock right now?: 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last year. There is currently 1 sell rating, 13 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BMY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BMY, but not buy additional shares or sell existing shares.
Does Bristol-Myers Squibb's stock price have much upside?: According to analysts, Bristol-Myers Squibb's stock has a predicted upside of 9.92% based on their 12-month stock forecasts.
Has Bristol-Myers Squibb been downgraded by Wall Street analysts recently?: Over the previous 90 days, Bristol-Myers Squibb's stock had 1 downgrade by analysts.
What analysts cover Bristol-Myers Squibb?: Bristol-Myers Squibb has been rated by research analysts at Barclays, Cantor Fitzgerald, Deutsche Bank Aktiengesellschaft, and TD Cowen in the past 90 days.
Do Wall Street analysts like Bristol-Myers Squibb more than its competitors?: Analysts like Bristol-Myers Squibb less than other "medical" companies. The consensus rating for Bristol-Myers Squibb is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BMY compares to other companies.